Recommendations and technical aspects of 16α-[18F]Fluoro-17β-Estradiol PET to image the estrogen receptor in vivo

Clinical Nuclear Medicine

Volumn 41, Issue 11, 2016, Pages 844-851

  Venema, Clasina M ^a   Apollonio, Giulia ^a   Hospers, Geke A P ^a   Schröder, Carolina P ^a   Dierckx, Rudi A J O ^a,b   De Vries, Erik F J ^a   Glaudemans, Andor W J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

breast cancer; FES PET; imaging; Key Words estrogen receptor expression; ovarian cancer

Indexed keywords

16ALPHA FLUOROESTRADIOL F 18; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; SEX HORMONE BINDING GLOBULIN; 16-FLUOROESTRADIOL; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BODY MASS; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL (TOPIC); ENDOMETRIUM SARCOMA; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MENINGIOMA; OVARY CANCER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; STOMACH CARCINOMA; UTERUS TUMOR; ANALOGS AND DERIVATIVES; BREAST TUMOR; DIAGNOSTIC IMAGING; FEMALE; IMAGE PROCESSING; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; PRACTICE GUIDELINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ESTRADIOL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN;

EID: 84986232207     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001347     Document Type: Article

References (42)

1. World Health Organization, www.who.int/cancer, accessed July 2016.
2. Alam IS, ArshadMA, Nguyen QD, et al. Radiopharmaceuticals as probes to characterize tumour tissue. Eur J NuclMedMol Imaging. 2015; 42: 537-561.
3. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMOclinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5): 8-30.
4. Chung GG, ZerkowskiMP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007; 87: 662-669.
5. Layfield LJ, Saria E, Mooney EE, et al. Tissue heterogeneity of immunohistochemically detected estrogen receptor: implications for image analysis quantification. Am J Clin Pathol. 1998; 110: 758-764.
6. van KruchtenM, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012; 53: 182-190.
7. PorterAJ, Evans EB, FoxcroftLM, et al.Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol. 2014; 58: 1-10.
8. Groheux D, Majdoub M, Tixier F, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)FFDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015; 42: 1682-1691.
9. HoganMP, GoldmanDA, Dashevsky B, et al. Comparison of 18F-FDG PET/.CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med. 2015; 56: 1674-1680.
10. van Kruchten M, de Vries EG, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013; 14: e465-e475.
11. Yoo J, Dence CS, Sharp TL, et al. Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R, 3S)-2, 3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16α-[18F]fluoro-17β-estradiol. J Med Chem. 2005; 48: 6366-6378.
12. van KruchtenM, de Vries EF, Arts HJ, et al. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT. J Nucl Med. 2015; 56: 50-55.
13. Tsujikawa T, Yoshida Y, Kiyono Y, et al. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-['8F]fluoro-17β-oestradiol PET. Eur J Nucl Med Mol Imaging. 2011; 38: 37-45.
14. Zhao Z, Yoshida Y, Kurokawa T, et al. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. J Nucl Med. 2013; 54: 499-506.
15. Yoshida Y, Kiyono Y, Tsujikawa T, et al. Additional value of 16α-18Ffluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET. Eur J Nucl Med Mol Imaging. 2011; 38: 1824-1831.
16. YoonG, KimTJ, Sung CO, et al. Benign metastasizing leiomyomawithmultiple lymph node metastasis: a case report. Cancer Res Treat. 2011; 43: 131-133.
17. van KruchtenM, Hospers GA, Glaudemans AW, et al. Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-Targeted therapy: case report and review of the literature. Eur J Cancer. 2013; 49: 3850-3855.
18. Yi JH, Do IG, Jang J, et al. Anti-Tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Sci Rep. 2014; 4: 7592.
19. Di Zazzo E, Galasso G, Giovannelli P, et al. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget. 2016; 7: 193-208.
20. Moresco RM, Scheithauer BW, Lucignani G, et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun. 1997; 18: 606-615.
21. PetersonLM, Kurland BF, Schubert EK, et al.A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity inmetastatic breast cancer (MBC). Mol Imaging Biol. 2014; 16: 431-440.
22. Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011; 17: 4799-4805.
23. van Kruchten M, Glaudemans AW, de Vries EF, et al. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur J Nucl Med Mol Imaging. 2015; 42: 1674-1681.
24. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of metabolic flare to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999; 26: 51-56.
25. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006; 24: 2793-2799.
26. van Kruchten M, de Vries EG, Glaudemans AW, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 2015; 5: 72-81.
27. Yang Z, Sun Y, Xue J, et al. Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?-A pilot study. PLoS One. 2013; 8: e78192.
28. Tsuchida T, Okazawa H, Mori T, et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET- influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol. 2007; 34: 205-210.
29. Moresco RM, Casati R, Lucignani G, et al. Systemic and cerebral kinetics of 16 alpha [18F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab. 1995; 15: 301-311.
30. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANMprocedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42: 328-354.
31. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol. 1997; 24: 341-348.
32. Mankoff DA, Peterson LM, Tewson TJ, et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001; 42: 679-684.
33. Rfmer J, Steinbach J, Kasch H. Studies on the synthesis of 16α-[18F]fluoroestradiol. Appl Radiat Isot. 1996; 47: 395-399.
34. Zou D, Lin M, Yasui N, et al. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F] fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alphadihydrotestosterone (FDHT) as radiopharmaceuticals. J Labelled Comp Radiopharm. 2014; 57: 371-377.
35. Römer J, Füchtner F, Steinbach J, et al. Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging. Nucl Med Bio. 1999; 26: 473-479.
36. Oh SJ, Chi DY, Mosdzianowski C, et al. The automatic production of 16alpha-[18F]fluoroestradiol using a conventional [18F]FDG module with a disposable cassette system. Appl Radiat Isot. 2007; 65: 676-681.
37. Peterson LM, Kurland BF, Link JM, et al. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol. 2011; 38: 969-978.
38. Tewson TJ, Mankoff DA, Peterson LM, et al. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999; 26: 905-913.
39. Nienhuis HH, van Kruchten M, Glaudemans AWJM, et al. FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression. J Clin Oncol. 2015; 33: 527.
40. Yang Z, Sun Y, Yao Z, et al. Increased (18)F-fluoroestradiol uptake in radiation pneumonia. Ann Nucl Med. 2013; 27: 931-934.
41. Couse JF, Lindzey J, Grandien K, et al. Tissue distribution and quantitative analysis of estrogen receptor-Alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-Type and ERalphaknockout mouse. Endocrinology. 1997; 138: 4613-4621.
42. Hattersley G, David F, Harris AL, et al. RAD1901, A novel tissue-selective estrogen receptor degrader demonstrates estrogen receptor engagement in a phase 1 clinical study. Cancer Res. 2015; 75: OT2-1-10.